Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

Reid EG, Looney D, Maldarelli F, Noy A, Henry D, Aboulafia D, et al. Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas. Blood Adv. 2018;2(24):3618-3626.

Chen Y-, Chen Z, Du Y-. Immunohistochemical analysis of RHAMM expression in normal and neoplastic human tissues: a cell cycle protein with distinctive expression in mitotic cells and testicular germ cells. Oncotarget. 2018;9(30):20941-20952.

Pal S, Postnikoff SD, Chavez M, Tyler JK. Impaired cohesion and homologous recombination during replicative aging in budding yeast. Sci Adv. 2018;4(2):eaaq0236.

Bonomo RA, Burd EM, Conly J, Limbago BM, Poirel L, Segre JA, et al. Carbapenemase-Producing Organisms: A Global Scourge. Clin Infect Dis. 2018;66(8):1290-1297.

Curtis BR, Hsu Y-, Podoltsev N, Lacy J, Curtis S, Samuel MS, et al. Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies. Blood. 2018;131(13):1486-1489.

Huang T-, Shen Z-, Sleckman BP, Tyler JK. The histone chaperone ASF1 regulates the activation of ATM and DNA-PKcs in response to DNA double-strand breaks. Cell Cycle. 2018;17(12):1413-1424.

Gold SL, Cohen-Mekelburg S, Rosenblatt R, Jessurun J, Sharaiha R, Halazun K, et al. An Overt, Obscure Gastrointestinal Bleed Caused by a Primary Small Bowel Fibroblastic Reticular Cell Sarcoma. ACG Case Rep J. 2018;5:e22.

Yang RK, Nazeef M, Patel SS, Mattison R, Yang DT, Ranheim EA, et al. Improving bone marrow biopsy quality through peer discussion and data comparisons: A single institution experience. Int J Lab Hematol. 2018;40(4):419-426.

Chedgy EC, Vandekerkhove G, Herberts C, Annala M, Donoghue AJ, Sigouros M, et al. Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma. J Pathol. 2018;246(2):244-253.

Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, Van Besien K, et al. The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data^. Leuk Lymphoma. 2018;59(1):256-258.